Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases

Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer

(2018) Matti Annala et al.   Cancer Discovery

AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide

(2017) Anna Katharina Seitz et al.   EUROPEAN UROLOGY

Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide

(2017) Emmanuel S. Antonarakis et al.   JOURNAL OF CLINICAL ONCOLOGY

Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer

(2016) Christine Henzler et al.   Nature Communications

Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer

(2016) Alexander W. Wyatt et al.   JAMA Oncology

Integrative Clinical Genomics of Advanced Prostate Cancer

(2015) Dan Robinson et al.   CELL

Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer

(2015) A. A. Azad et al.   CLINICAL CANCER RESEARCH

The evolutionary history of lethal metastatic prostate cancer

(2015) Gunes Gundem et al.   NATURE

Plasma AR and abiraterone-resistant prostate cancer

(2015) Alessandro Romanel et al.   Science Translational Medicine

Recurrent SKIL-activating rearrangements in ETS-negative prostate cancer

(2015) Matti Annala et al.   Oncotarget

Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer

(2015) Emmanuel S. Antonarakis et al.   JAMA Oncology

Detecting predictive androgen receptor modifications in circulating prostate cancer cells

(2015)   Oncotarget

Rapid Induction of Androgen Receptor Splice Variants by Androgen Deprivation in Prostate Cancer

(2014) Z. Yu et al.   CLINICAL CANCER RESEARCH

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

(2014) Emmanuel S. Antonarakis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor clone dynamics in lethal prostate cancer

(2014) S. Carreira et al.   Science Translational Medicine

Loss of PTEN Is Associated with Aggressive Behavior in ERG-Positive Prostate Cancer

(2013) K. A. Leinonen et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Mechanisms of the androgen receptor splicing in prostate cancer cells

(2013) L L Liu et al.   ONCOGENE

Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer

(2012) R. Hu et al.   CANCER RESEARCH

The androgen receptor gene mutations database: 2012 update

(2012) Bruce Gottlieb et al.   HUMAN MUTATION

The mutational landscape of lethal castration-resistant prostate cancer

(2012) Catherine S. Grasso et al.   NATURE

Fast gapped-read alignment with Bowtie 2

(2012) Ben Langmead et al.   NATURE METHODS

AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression

(2012) Y Li et al.   ONCOGENE

Intragenic Rearrangement and Altered RNA Splicing of the Androgen Receptor in a Cell-Based Model of Prostate Cancer Progression

(2011) Y. Li et al.   CANCER RESEARCH

Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy

(2011) Changmeng Cai et al.   ENDOCRINE-RELATED CANCER

Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival

(2011) Emma Hörnberg et al.   PLoS One

BEDTools: a flexible suite of utilities for comparing genomic features

(2010) Aaron R. Quinlan et al.   BIOINFORMATICS

Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant

(2010) Shihua Sun et al.   JOURNAL OF CLINICAL INVESTIGATION

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study

(2010) Howard I Scher et al.   LANCET

ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data

(2010) K. Wang et al.   NUCLEIC ACIDS RESEARCH

The Sequence Alignment/Map format and SAMtools

(2009) H. Li et al.   BIOINFORMATICS

Increased Expression of Androgen Receptor Sensitizes Prostate Cancer Cells to Low Levels of Androgens

(2009) K. K. Waltering et al.   CANCER RESEARCH

A Novel Androgen Receptor Splice Variant Is Up-regulated during Prostate Cancer Progression and Promotes Androgen Depletion-Resistant Growth

(2009) Z. Guo et al.   CANCER RESEARCH

The Role of Androgen Receptor Mutations in Prostate Cancer Progression

(2009) G. Brooke et al.   CURRENT GENOMICS

Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer

(2009) Gerhardt Attard et al.   JOURNAL OF CLINICAL ONCOLOGY

Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

(2009) C. Tran et al.   SCIENCE

Splicing of a Novel Androgen Receptor Exon Generates a Constitutively Active Androgen Receptor that Mediates Prostate Cancer Therapy Resistance

(2008) S. M. Dehm et al.   CANCER RESEARCH

Androgen Levels Increase by Intratumoral De novo Steroidogenesis during Progression of Castration-Resistant Prostate Cancer

(2008) J. A. Locke et al.   CANCER RESEARCH

Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth

(2008) R. B. Montgomery et al.   CANCER RESEARCH

Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer

(2008) R. Hu et al.   CANCER RESEARCH